Avecho Biotechnology Past Earnings Performance
Past criteria checks 0/6
Avecho Biotechnology's earnings have been declining at an average annual rate of -19.8%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been declining at an average rate of 36.5% per year.
Key information
-19.8%
Earnings growth rate
-14.4%
EPS growth rate
Pharmaceuticals Industry Growth | 31.2% |
Revenue growth rate | -36.5% |
Return on equity | -53.9% |
Net Margin | -725.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth
Jan 13Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation
May 31Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely
Jul 14We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth
Mar 23We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate
Dec 08Revenue & Expenses BreakdownBeta
How Avecho Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -3 | 2 | 1 |
30 Sep 23 | 1 | -4 | 3 | 1 |
30 Jun 23 | 1 | -4 | 3 | 1 |
31 Mar 23 | 1 | -3 | 3 | 1 |
31 Dec 22 | 1 | -2 | 2 | 1 |
30 Sep 22 | 1 | -2 | 2 | 1 |
30 Jun 22 | 1 | -2 | 3 | 1 |
31 Mar 22 | 1 | -3 | 3 | 1 |
31 Dec 21 | 1 | -3 | 3 | 1 |
30 Sep 21 | 1 | -3 | 3 | 1 |
30 Jun 21 | 0 | -3 | 3 | 1 |
31 Mar 21 | 0 | -3 | 3 | 0 |
31 Dec 20 | 0 | -3 | 3 | 0 |
30 Sep 20 | 0 | -2 | 2 | 0 |
30 Jun 20 | 0 | -2 | 2 | 0 |
31 Mar 20 | 2 | -1 | 2 | 0 |
31 Dec 19 | 4 | 1 | 2 | 0 |
30 Sep 19 | 4 | 1 | 2 | 0 |
30 Jun 19 | 5 | 0 | 3 | 0 |
31 Mar 19 | 3 | -2 | 3 | 0 |
31 Dec 18 | 1 | -4 | 4 | 0 |
30 Jun 18 | 1 | -6 | 6 | 1 |
31 Mar 18 | 1 | -7 | 7 | 1 |
31 Dec 17 | 1 | -9 | 8 | 1 |
30 Jun 17 | 1 | -16 | 8 | 1 |
31 Mar 17 | 1 | -17 | 8 | 1 |
31 Dec 16 | 2 | -17 | 8 | 2 |
30 Sep 16 | 2 | -17 | 9 | 2 |
30 Jun 16 | 3 | -17 | 9 | 2 |
31 Mar 16 | 2 | -18 | 9 | 2 |
31 Dec 15 | 2 | -20 | 9 | 2 |
30 Sep 15 | 2 | -17 | 8 | 2 |
30 Jun 15 | 3 | -14 | 7 | 3 |
31 Mar 15 | 2 | -10 | 6 | 3 |
31 Dec 14 | 2 | -7 | 6 | 3 |
30 Jun 14 | 1 | -7 | 6 | 3 |
31 Mar 14 | 1 | -9 | 7 | 3 |
31 Dec 13 | 1 | -11 | 7 | 4 |
30 Sep 13 | 1 | -12 | 9 | 3 |
30 Jun 13 | 1 | -11 | 8 | 3 |
Quality Earnings: AVE is currently unprofitable.
Growing Profit Margin: AVE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AVE is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.
Accelerating Growth: Unable to compare AVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16%).
Return on Equity
High ROE: AVE has a negative Return on Equity (-53.88%), as it is currently unprofitable.